Global Markets

Shingrix sales bounce back post-pandemic for GSK

GSK says its vaccine turnover for this quarter benefited from Shingrix’s post-pandemic recovery in the US and Europe. For the first quarter 2022, GlaxoSmithKline (GSK) reported its vaccine business made a total of ÂŁ1.7 billion ($2.1 billion) in sales. ÂŁ698 million ($866 million) of this was made up of Shingrix sales, the firm’s non-live, recombinant subunit vaccine for the prevention of shingles (herpes zoster). According to GSK, its vaccine business benefited from Shingrix’s “strong demand recovery.” The firm claims it…

Novartis CGTs first quarter 2022: Zolgensma up, Kymriah down

Novartis reports increased sales for gene therapy Zolgensma due to expanded global access, but the failure in the second-line DLBCL setting will affect Kymriah sales. For Swiss Pharma giant Novartis’ cell and gene therapy (CGT) division, first quarter 2022 results were mixed. On the positive side, Zolgensma (onasemnogene abeparvovec) pulled in $363 million during the quarter, up 18% year-on-year due to increased access outside of the US. Sales of the one-time spinal muscular atrophy (SMA) gene therapy — approved in the…

China’s I-Mab allegedly seeking asset or company sale

Shanghai-based I-Mab is in talks with global drugmakers about a potential sale of the whole company or its oncological assets, according to a Bloomberg article. The Bloomberg article claims US and EU pharmas were interested in I-Mab, given its portfolio of 10 clinical stage oncology antibodies plus access to the world’s second largest pharmaceutical market. Bloomberg noted that I-Mab has lost three-fourths of its market value since the prices for pharmaceutical companies peaked in June 2021. When it announced its…

Danaher and Sartorius: COVID just one variable affecting bioprocess growth

Comments from J&J have led to questions surrounding the long-term revenues from COVID-19 vaccines. However, the sector is just one area driving bioprocess growth, both Danaher and Sartorius say. While the COVID-19 virus is still virulent in some areas, the rapid development, scale-up, and delivery of vaccines over the past two years has helped bring the world back to some sense of normality. The unprecedented roll-out has resulted in hundreds-of-billions of dollars ending up in the pockets of several vaccine…

China: US auditors can examine US-listed companies in policy change

China plans to furnish US auditors with full access to the financial records of China companies that have US listings. The change seems to solve a looming crisis between the two countries, as the US is currently threatening to de-list all China companies that closed their financial documents to US auditors. The revised regulation will allow scrutiny of China-based companies’ books, while detailing how to handle national security information, which will remain protected. The new policy was announced earlier this…

German pandemic prep wins for GSK, CureVac, Wacker, and more

As part of a pandemic preparedness plan, Germany has struck several deals to secure manufacturing capacity for hundreds-of-millions of doses of mRNA-based vaccines. To support the continued COVID-19 pandemic and to be better prepared for future health crises, Germany has secured messenger RNA (mRNA) vaccine manufacturing capacity across a range of partners. The first deal, announced last week, sees German vaccine maker BioNTech reserve and maintain manufacturing capabilities to produce at least 80 million mRNA-based vaccine doses per year for…

Cash strapped Bluebird cuts staff and focuses on late stage gene therapies

Bluebird Bio is cutting its workforce and prioritizing late phase gene therapy projects to reduce costs. The US biotech announced the staff cuts this week, explaining the aim is to deliver up to $160 million in operational savings over the next two years. It did not share further details. At the start of the year, Massachusetts-based Bluebird said it employed 518 people, 330 of whom work in R&D with 188 engaged in commercial, finance, legal, business development, human resources, information technology,…

Insider State of the Industry: Ukraine, supply chains, and CDMO gains

Another quarter, another industry snapshot. We sat down with experts at BPI West to discuss the current state of biomanufacturing. Our State of the Industry series began last year to allow reflection on quarterly trends within the bioprocess and manufacturing sector. Clearly the pandemic has driven much of the conversation, but in a sign of COVID’s decline this quarter’s panel was held not on Zoom, Teams, or Skype but in a real face-to-face setting: BPI West in San Diego. Our…

Merck completes $1bn HPV vaccine expansion in Virginia

Merck & Co. has added 120,000 square feet of manufacturing capacity at its Rockingham County site to support continued scale-up of its Gardasil HPV vaccines. Human papillomavirus (HPV) vaccines Gardasil and Gardasil 9 pulled in $1.5 billion for Merck last year, and while the firm has predicted sales to double by 2030 as demand continues, this is reliant on having the manufacturing capacity in place. With this in mind, it is good news today for Merck as it announces the…

BioProcess Insider State of the Industry – Live from BPI West, March 2022

BioProcess Insider’s State of the Industry takes a deeper look into the recent business news affecting the biomanufacturing industry, picking apart the numbers and highlighting potential trends. With a panel of industry experts, editor Dan Stanton discusses recent mergers and acquisitions in the bioprocess space, bottlenecks within the manufacturing sector, the continued head- and tailwinds COVID-19 is placing on businesses, and the evolution of the cell and gene therapy landscape and what that means for supply chains. Panelists: Frank Orlowski,…